StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30243% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Zetia (ezetimibe, legacy pre-Organon spin-off) by Quarter

Zetia (ezetimibe, legacy pre-Organon spin-off) — U.S. reported growth YoY (%) (%)

QuarterlyAnnual

Merck Zetia (ezetimibe, legacy pre-Organon spin-off): -199.0% in Q1 2021. That is the lowest of the 11 quarters on record here. No newer figure appears in the documents we track.

Latest, Q1 2021
-199.0%
Period ended Mar 31, 2021
Change on a year earlier
–
History
11 quarters
Since Q4 2017
Sources
11
Documents cited below

Where the Q1 2021 figure comes from

“|| Zetia | 92 | 145 | -37 | 2 | (2 | ) | -199 | 90 | 147 | -39”

Source: Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZetia (ezetimibe, legacy pre-Organon spin-off) — U.S. reported growth YoY (%) (%)Year on yearSource
Q1 2021Mar 31, 2021-199.0%–Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q3 2020Sep 30, 2020-115.0%-71.0 ptsForm 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 2020-123.0%-96.0 ptsForm 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q4 2019Dec 31, 2019-73.0%+7.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 2019-44.0%+42.0 ptsForm 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2019Jun 30, 2019-27.0%+66.0 ptsForm 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q4 2018Dec 31, 2018-80.0%+4.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2018Sep 30, 2018-86.0%–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2018Jun 30, 2018-93.0%–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗
Q1 2018Mar 31, 2018-84.0%–Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗
Q4 2017Dec 31, 2017-84.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Zetia (ezetimibe, legacy pre-Organon spin-off) (%), quarterly Q4 2017–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zetia-us-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.

See a number that looks wrong?